Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatocellular carcinoma (histology or Barcelona criteria) curatively treated by surgical resection or by radiofrequency or by cryotherapy~* Evidence of liver cirrhosis (clinical, biological, endoscopic or histological criteria)~* Morphological evaluation 4 to 6 weeks following curative treatment~* No evidence of local or distant disease on the morphological evaluation~* Absence of peritoneal or lymph node metastasis~* Absence of pre- or per-operative macroscopic tumoral thrombus~* Minimal free margin of 5 mm following pathological exam~* ALPHAAFOETOPROTEINE level of less than 4 normal values or decreased by 50%, 4 to 6 weeks following curative treatment~* Biological criteria, 2 weeks before treatment as follow:~  * neutrophilic polymorphonuclear \> 1500/mm3,~ * platelets \> 100 000/mm3,~ * total bilirubin \< 25 mmol/l (1.46 mg/dl),~ * creatinin \< 1.5 x normal value~* Eastern Cooperative Oncology Group (ECOG) equal to 0 or 1~* Life expectancy \> 12 weeks~* Absence of sensitive neuropathy at inclusion time~* Health insurance coverage~* Efficient contraceptive method if applicable~* Signed informed consent~Exclusion Criteria:~* Curative treatment performed 10 weeks or more before the beginning of adjuvant treatment~* Contraindication to an angiography or hepatic artery thrombosis or portal thrombosis.~* Pregnant or breastfeeding woman~* Concomitant involvement to any clinical trial~* Decompensate cirrhosis and Child-Pugh score ≥ 8 or clinical ascitis.~* Cancer of the Liver Italian Program (C.L.I.P.) score ≥ 2~* Heart or lung insufficiency~* Other cancer not considered as definitively cured~* Creatinin clearance \< 30 ml/min~* Recurrence of HCC less than 12 months following any last treatment~* Any radiotherapy during the 4 weeks before inclusion~* Known sensitivity to any drug of this protocol~* Immunodeficiency (HIV+, transplanted patient)~* Inability of follow up~* Impossibility of clear understanding of the protocol for no french speaking patient~* Patient under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oxaliplatin, gemcitabine, cisplatin, lipiodol
- 2 (Type: EXPERIMENTAL): Oxaliplatin, gemcitabine, cisplatin, lipiodol

Based on this trial design, predict the completion outcome and termination type (if applicable).